Zai Lab LTD Form 4 insider transactions

Zai Lab's Chief Legal Officer, Frazor Titus Edmondson III, sold 15,569 American Depositary Shares for approximately $297,000 pursuant to a pre-arranged trading plan.

Zai Lab's Chairperson and CEO, Du Ying, exercised stock options and subsequently sold a significant number of American Depositary Shares under a pre-arranged trading plan.

Zai Lab's President of Global Oncology R&D, Rafael Amado, sold 10,000 American Depositary Shares at $17.38 each under a pre-arranged trading plan.

Zai Lab's President of Global Oncology R&D, Rafael Amado, reported the vesting of Restricted Share Units and a subsequent sale of shares to cover tax obligations.

Zai Lab's Chief Legal Officer, Frazor Titus Edmondson III, sold 8,651 American Depositary Shares at $17.14 each pursuant to a pre-arranged trading plan.

Zai Lab's Chairperson and CEO, Du Ying, reported a gift of American Depositary Shares to a trust and subsequent annuity payment from the trust.

Zai Lab's Chief Legal Officer, Frazor Titus III Edmondson, reported the sale of 14,328 American Depositary Shares at $19.78 per share, executed under a pre-arranged 10b5-1 trading plan.

Zai Lab's Chief Financial Officer, Yajing Chen, reported the vesting of Restricted Share Units and a subsequent sale of shares to cover tax obligations.

Zai Lab's Chief Financial Officer, Yajing Chen, reported the vesting of 920 Restricted Share Units into American Depositary Shares and a subsequent sale of 456 ADSs to cover tax obligations.

Zai Lab's President and COO, Joshua L. Smiley, purchased 10,000 ADSs on September 10, 2025, and agreed to pay $72,111.22 to the company for short-swing profits from prior sales.

Zai Lab's Chairperson and CEO, Du Ying, exercised stock options for 604,376 American Depositary Shares and subsequently sold 251,319 shares to cover tax obligations.

Zai Lab's President and COO, Joshua L. Smiley, acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.

Zai Lab's Chief Legal Officer, Frazor Titus Edmondson III, reported the vesting of 4,850 Restricted Share Units and the subsequent sale of 1,883 American Depositary Shares to cover tax obligations.

Zai Lab's Chief Financial Officer, Chen Yajing, reported the vesting of Restricted Share Units and subsequent sale of American Depositary Shares, including tax-related sales and a Rule 10b5-1 plan transaction.

Zai Lab's Chairperson and CEO, Du Ying, executed pre-planned sales of American Depositary Shares totaling approximately $3.3 million through option exercises.

Zai Lab's President of Global Oncology R&D, Rafael Amado, reported a future sale of 3,000 American Depositary Shares at $35 each, executed under a pre-arranged 10b5-1 trading plan.

Zai Lab's Chief Financial Officer, Yajing Chen, sold 4,096 American Depositary Shares for $34.01 each, reducing her direct holdings to 16,908 ADSs, as part of a pre-arranged trading plan.

Zai Lab's Chairperson and CEO, Du Ying, executed pre-planned sales of American Depositary Shares totaling approximately $3.4 million in August 2025.

Zai Lab Ltd's Chairperson and CEO, Du Ying, was granted 44,194 Restricted Share Units, aligning executive incentives with long-term company performance.

Zai Lab's Chairperson and CEO, Du Ying, reported the vesting of 18,000 Restricted Share Units and a subsequent tax-related sale of 7,072 American Depositary Shares.

Zai Lab's Chairperson and CEO, Du Ying, reported the acquisition of 17,970 American Depositary Shares (ADSs) from RSU vesting and a subsequent sale of 6,918 ADSs to cover tax obligations.

Zai Lab's Chief Financial Officer, Yajing Chen, reported the vesting of 6,250 Restricted Share Units and a subsequent sale of 2,675 American Depositary Shares to cover tax obligations.

Zai Lab Ltd.'s Chief Legal Officer, Frazor Titus Edmondson III, reported the vesting of Restricted Share Units and a subsequent sale of American Depositary Shares to cover tax obligations.

Zai Lab Ltd's Chairperson and CEO, Du Ying, reported the vesting of 58,800 Restricted Share Units into American Depositary Shares, followed by the sale of 23,669 ADSs to cover tax obligations.

Zai Lab Ltd. Director Peter Wirth has acquired 10,831 American Depositary Shares (ADSs) as a restricted stock grant, aligning his interests with shareholders.

Zai Lab Ltd. Director Michel Vounatsos was granted 10,831 restricted American Depositary Shares, vesting in June 2026, as part of his compensation.

Zai Lab Ltd. Director Leon O. Moulder Jr. was granted 10,831 American Depositary Shares (ADSs) as part of his compensation, which are set to vest in June 2026.

Zai Lab Ltd. Director Scott W. Morrison has been granted 10,831 American Depositary Shares (ADSs) as restricted stock, increasing his beneficial ownership in the company.

Zai Lab Ltd. Director Richard Gaynor has been granted 10,831 restricted American Depositary Shares (ADSs) as part of his compensation, vesting in June 2026.

Zai Lab Ltd. Director John D. Diekman was granted 10,831 American Depositary Shares (ADSs) as restricted stock, which will vest on June 18, 2026.